Yanhong Deng
Statistician 3DownloadHi-Res Photo
Cards
Additional Titles
Senior Biostatistician
Co-Director of Analytics, Yale Center for Analytical Sciences
Contact Info
About
Copy Link
Titles
Statistician 3
Senior Biostatistician; Co-Director of Analytics, Yale Center for Analytical Sciences
Departments & Organizations
Research
Copy Link
Research Projects
Understanding the Impact of COVID-19 on Individuals with HIV with Tobacco Use: A Mixed-Methods Study
General Internal Medicine / , parent organization of Phoenix LabA SMART Approach to Treating Tobacco Use Disorder in Persons Living with HIV (SMARTTT)
General Internal Medicine / , parent organization of Phoenix Lab
ORCID
0000-0001-6873-8026
Research at a Glance
Yale Co-Authors
Frequent collaborators of Yanhong Deng's published research.
Publications Timeline
A big-picture view of Yanhong Deng's research output by year.
Geliang Gan, MPH, PhD
James Dziura, MPH, PhD
Jingchen Liang
Stephen Parziale, MSc
Aron Flagg, MD
Dhanpat Jain, MD, MBBS
229Publications
6,327Citations
Publications
2026
A phase III, randomized, open-label study of tunlametinib plus vemurafenib versus investigator's choice of therapy in patients with previously treated BRAFV600E-mutant metastatic colorectal cancer.
Xu T, Li J, Wang J, Deng Y, Meng Q, Niu Z, Fan N, Yuan X, Deng J, Fang X, Zhang Y, Tian H, Liu W, Shen L. A phase III, randomized, open-label study of tunlametinib plus vemurafenib versus investigator's choice of therapy in patients with previously treated BRAFV600E-mutant metastatic colorectal cancer. Journal Of Clinical Oncology 2026, 44: lba3509-lba3509. DOI: 10.1200/jco.2026.44.17_suppl.lba3509.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerObjective response rateProgression-free survivalBRAF V600E-mutated mCRCPhase III randomized controlled trialsOpen-label studyOverall survivalMutant non-small cell lung cancerColorectal cancerHazard ratioNon-small cell lung cancerBRAF/MEK inhibitor combinationData cutoff dateStratified log-rank testChemotherapy-based regimensPermanent treatment discontinuationAll-oral regimenPhase I/II dataPhase III trialsBRAF V600E mutationIndependent review committeePhase I trialCell lung cancerInvestigator's choiceLog-rank testPreliminary efficacy of GFH375 in patients with advanced cholangiocarcinoma or colorectal cancer harboring KRAS G12D mutation.
Zhu L, Deng Y, Zong H, Zhao H, Zhou A, Zhao L, Wu L, Li Z, Zhang J, Yuan Y, Li Z, Sun Y, Niu Z, Sun M, Song Z, Liu H, Wang Y, Shen H, Zheng C, Shan Y. Preliminary efficacy of GFH375 in patients with advanced cholangiocarcinoma or colorectal cancer harboring KRAS G12D mutation. Journal Of Clinical Oncology 2026, 44: 3008-3008. DOI: 10.1200/jco.2026.44.16_suppl.3008.Peer-Reviewed Original ResearchConceptsDisease control rateProgression-free survivalKirsten rat sarcomaMedian progression-free survivalTreatment-related adverse eventsMedian prior linesCirculating tumor DNAPreliminary efficacy resultsColorectal cancerG12D mutationStable diseaseMetastatic diseaseOverall survivalTumor assessmentMetastatic cholangiocarcinomaNon-small cell lung cancerResistant to conventional chemotherapyLater-line therapyMedian overall survivalPhase I/II studyAssociated with poor prognosisAdvanced solid tumorsCell lung cancerCo-mutated genesAnti-tumor therapyPhase 3 trial of trastuzumab rezetecan vs standard of care (SOC) for chemotherapy-refractory, HER2-positive, advanced colorectal cancer (CRC).
Li J, Yuan Y, Liu T, Xiao X, Wang Y, Zhang F, Niu Z, Deng Y, Meng Q, Zong H, Chen Y, Gao X, Zhou J, Li X, Shen Y, Dou N, Huang C. Phase 3 trial of trastuzumab rezetecan vs standard of care (SOC) for chemotherapy-refractory, HER2-positive, advanced colorectal cancer (CRC). Journal Of Clinical Oncology 2026, 44: 3505-3505. DOI: 10.1200/jco.2026.44.16_suppl.3505.Peer-Reviewed Original ResearchConceptsAdvanced colorectal cancerPhase 3 trialStandard of careECOG PSHER2-positiveColorectal cancerAntibody-drug conjugatesChemotherapy-refractoryHER2 IHC 3+HER2-positive gastric cancerStratified log-rank testTreatment-related deathsMedian Follow-UpLog-rank testCochran-Mantel-Haenszel testRisk of deathMedian OSProlonged PFSRECIST v1.1Data cutoffHER2 statusOpen-labelStandard therapyPrimary endpointSafety profileSHR-A1811 plus chemotherapy and BP102 as 1L therapy for HER2-expressing mCRC: Data from a phase Ib/II study.
Xu T, Shen L, Li J, Deng Y, Li H, Yang W, Liu Z, Zhang Y, Wang Q, Gu Y, Liang X, Zong H, Li Y, Wang Z, Jin Y, Yu A, Yingyi J, Huang C. SHR-A1811 plus chemotherapy and BP102 as 1L therapy for HER2-expressing mCRC: Data from a phase Ib/II study. Journal Of Clinical Oncology 2026, 44: 3569-3569. DOI: 10.1200/jco.2026.44.16_suppl.3569.Peer-Reviewed Original ResearchConceptsPhase Ib/II studyPlus chemotherapyTopoisomerase I inhibitor payloadPhase II regimenAssociated with poor prognosisWild-type diseaseMedian Follow-UpWhite blood cell countHuman monoclonal antibodyBlood cell countPreliminary efficacyCTCAE v5.0L-LVRECIST v1.1ECOG PSData cutoffHER2-positiveTumor responseDose reductionLiver metastasesOpen-labelHER2 expressionMedian ageNeutrophil countPoor prognosisIvonescimab (ivo) with oxaliplatin + fluorouracil (5-FU) + leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase 2 study.
Berz D, Deng Y, Zhang J, Li Z, Yin M, Zhao J, Eckert K, Paranthaman N, Yu X, Xia Y, Spira A. Ivonescimab (ivo) with oxaliplatin + fluorouracil (5-FU) + leucovorin calcium (mFOLFOX6) for patients (pts) with unresectable metastatic colorectal cancer (mCRC): A phase 2 study. Journal Of Clinical Oncology 2026, 44: 3576-3576. DOI: 10.1200/jco.2026.44.16_suppl.3576.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsMetastatic colorectal cancerProgression-free survivalDisease control rateMFOLFOX6 armFirst-line treatmentSafety profileTreatment armsFirst-line treatment of metastatic colorectal cancerSeverity of treatment-emergent adverse eventsFollow-upTreatment of metastatic colorectal cancerMedian progression-free survivalMultiple phase 3 studiesSystemic anti-tumour therapyProgression-free survival ratesUnresectable metastatic colorectal cancerUntreated metastatic colorectal cancerEastern Cooperative Oncology Group scoreNon-small cell lung cancerProgrammed death protein 1BRAF tumor mutationsRadical surgical resectionLeft-sided tumorsMedian Follow-UpCadonilimab, a bispecific anti–PD-1/CTLA-4 antibody, for patients with dMMR/MSI-H metastatic colorectal cancer after progression on anti–PD-(L)1 therapy: A multicenter, single-arm, phase 2 trial (CSWOG-C03).
Hu H, Zheng Z, Deng J, Xie L, Zhang J, Zhang Y, Zhai X, Xie X, Wu Z, Li W, Cao W, Li F, Hu J, Yang T, Wang C, Zeng S, Shi L, Deng Y. Cadonilimab, a bispecific anti–PD-1/CTLA-4 antibody, for patients with dMMR/MSI-H metastatic colorectal cancer after progression on anti–PD-(L)1 therapy: A multicenter, single-arm, phase 2 trial (CSWOG-C03). Journal Of Clinical Oncology 2026, 44: 3577-3577. DOI: 10.1200/jco.2026.44.16_suppl.3577.Peer-Reviewed Original ResearchConceptsAnti-PD-(L)1 therapyAnti-PD-(L)1Metastatic colorectal cancerProgression-free survivalDisease control rateDisease progressionOverall survivalPrimary endpointSingle-armStudy treatmentTreated with anti-PD-1 monotherapyColorectal cancerAnti-PD-(L)1 monotherapyAnti-PD-1 monotherapyMedian progression-free survivalProgression-free survival ratesTreatment-related adverse eventsGrade 3 eventsImmune checkpoint blockadeMedian overall survivalMedian Follow-UpPhase 2 studyPhase 2 trialStandard of careMicrosatellite instability-highA multicenter randomized phase II trial assessing the efficacy and safety of mCapOX plus cetuximab with mFOLFOX6 plus cetuximab as first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer: Updated results from the CAPCET study.
Meng Q, Zhou Y, Chen P, Wang J, Jin Y, Li Y, Chen C, Qiu H, Shen Y, Qiao Q, Liu H, Huang L, Xie L, Deng Y, Yang L, Zhang L, Li X, Li J, Tan S, Zhang T. A multicenter randomized phase II trial assessing the efficacy and safety of mCapOX plus cetuximab with mFOLFOX6 plus cetuximab as first-line treatment for RAS/BRAF wild-type metastatic colorectal cancer: Updated results from the CAPCET study. Journal Of Clinical Oncology 2026, 44: 3598-3598. DOI: 10.1200/jco.2026.44.16_suppl.3598.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerFirst-line treatmentProgression-free survivalRAS/BRAF wild-type metastatic colorectal cancerWild-type metastatic colorectal cancerDisease control rateArm AOverall response rateArm BOverall survivalPrimary endpointIntention-to-treatArm A/BChinese willingness-to-pay thresholdCost-effective first-line treatmentPer-protocolColorectal cancerMulticenter randomized phase II trialRandomized phase II trialIntention-to-treat populationTreatment-free intervalMedian Follow-UpPhase II trialWillingness-to-pay thresholdsNon-comparative trialsAssociation of CT-based deep learning–derived consensus molecular subtypes with survival outcomes in locally advanced colon cancer: A secondary analysis of the phase III OPTICAL trial.
Qi S, Xu C, Li C, Nie X, Zhang J, Hu H, Wang X, Deng Y. Association of CT-based deep learning–derived consensus molecular subtypes with survival outcomes in locally advanced colon cancer: A secondary analysis of the phase III OPTICAL trial. Journal Of Clinical Oncology 2026, 44: 3639-3639. DOI: 10.1200/jco.2026.44.16_suppl.3639.Peer-Reviewed Original ResearchConceptsLocally advanced colon cancerDisease-free survivalConsensus molecular subtypesDisease-free survival ratesNeoadjuvant chemotherapyAdvanced colon cancerOverall survivalSurvival outcomesMolecular subtypesColon cancerColorectal cancerCMS subtypesAssociated with favorable prognosisConsensus molecular subtype classificationStratification of colorectal cancerMultivariate Cox proportional hazards regression modelsContrast-enhanced CT imagesAssociated with superior prognosisNeoadjuvant chemotherapy groupUpfront surgery groupMedian Follow-UpCox proportional hazards regression modelsProportional hazards regression modelsBiological stratificationHazards regression modelsPhase I/II trial of anti-CLDN18.2/PD-L1 recombinant humanized bispecific antibody Q-1802 plus XELOX in treatment-naive CLDN18.2-positive advanced GC/GEJ.
Gong J, Wang Y, Sun Y, Ni S, Yang J, Zhang Y, Yang W, Yang L, Li J, Liu T, Shi J, Zhao H, Wang X, Zhang J, Deng Y, Kou X, Nie P, Chen Y, Qu X, Shen L. Phase I/II trial of anti-CLDN18.2/PD-L1 recombinant humanized bispecific antibody Q-1802 plus XELOX in treatment-naive CLDN18.2-positive advanced GC/GEJ. Journal Of Clinical Oncology 2026, 44: 4036-4036. DOI: 10.1200/jco.2026.44.16_suppl.4036.Peer-Reviewed Original ResearchConceptsMedian progression-free survivalAntibody-dependent cellular cytotoxicityPhase I/II trialFirst-line therapyPD-L1Overall survivalTumor cellsFc-mediated antibody-dependent cellular cytotoxicityTreatment-related deathsProgression-free survivalPhase III trialsPD-1/PD-L1 bindingHigher expressionHumanized bispecific antibodyTight junction proteinsNormal gastric mucosaCLDN18.2-positiveHER2-negativePermanent discontinuationOpen-labelCLDN18.2 expressionIII trialsALT increaseCellular cytotoxicityCLDN18.2PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer
Cai R, Zhan W, Lyu X, Yang X, Wu Z, Cheng Y, Guo C, Feng J, Fu Y, Xie Y, Qin G, Deng Y, Zhang J. PTEN deficiency impairs MHC-I-mediated tumour immunity via NRF2-dependent autophagy in microsatellite stable colorectal cancer. Gut 2026, gutjnl-2026-338195. PMID: 42173678, DOI: 10.1136/gutjnl-2026-338195.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeMSS colorectal cancerColorectal cancerPTEN deficiencyAnti-programmed cell death protein 1 therapyResistance to immune checkpoint blockadeCD8+ T cell infiltrationImmune evasionImmune checkpoint blockade resistancePharmacological inhibitionCD8+ T cell recognitionFunction of PTENMicrosatellite stable colorectal cancerImmunosuppressive tumor microenvironmentEfficacy of immunotherapyT cell infiltrationSurface MHC-I levelsTumor immune microenvironmentMHC-I levelsPharmacological inhibition of Nrf2Loss of phosphataseStable colorectal cancerT cell recognitionNon-canonical functionsInhibition of Nrf2
News
Copy Link
News
- March 02, 2026
Integrating Tobacco Treatment in HIV Care
- May 29, 2024
Renalase May Predict Post-ERCP Pancreatitis
- January 11, 2023
Discoveries & Impact (January 2023)
- June 15, 2021
Pneumocystis Pneumonia Outbreak Chronicled In Clinical Infectious Diseases
Get In Touch
Copy Link
Contacts
Locations
300 George Street
Academic Office
Ste Suite 555
New Haven, CT 06511